The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus.
about
Chemical Modification of Influenza CD8+ T-Cell Epitopes Enhances Their Immunogenicity Regardless of ImmunodominanceConsiderations for the rapid deployment of vaccines against H7N9 influenza.Prior population immunity reduces the expected impact of CTL-inducing vaccines for pandemic influenza control.Synthetic Long Peptide Influenza Vaccine Containing Conserved T and B Cell Epitopes Reduces Viral Load in Lungs of Mice and Ferrets.Conserved epitopes dominate cross-CD8+ T-cell responses against influenza A H1N1 virus among Asian populations.The prospects and challenges of universal vaccines for influenzaFast vaccine design and development based on correlates of protection (COPs).Physical detection of influenza A epitopes identifies a stealth subset on human lung epithelium evading natural CD8 immunityGeneration of Adaptive Immune Responses Following Influenza Virus Challenge is Not Compromised by Pre-Treatment with the TLR-2 Agonist Pam2CysInnate immunity based cancer immunotherapy: B16-F10 murine melanoma model.T cell responses to viral infections - opportunities for Peptide vaccination.Challenges and solutions for a rational vaccine design for TB-endemic regions.TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease.Development of cross-protective influenza a vaccines based on cellular responses.Lineage-specific epitope profiles for HPAI H5 pre-pandemic vaccine selection and evaluation.Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8+ T cell epitope.Whole-Inactivated Influenza Virus Is a Potent Adjuvant for Influenza Peptides Containing CD8+ T Cell Epitopes.
P2860
Q28552025-B4E679A5-D148-4374-9FD6-FEFF169CA806Q30364635-008E817D-3653-4A65-8222-A694FAEFFDF7Q30373077-E40D9C73-60BF-4E4F-B220-9E1F00070EFBQ30375348-4CEB994C-11A5-4EAB-9874-A612E1B6B02EQ30430651-18036E4B-606C-4FC7-8354-644F55AB55FBQ30430703-EAF3F8D9-E4BB-462E-81BA-2C80B6853D9CQ34291098-B7C0C713-9420-494B-806B-D33263242C6DQ35128920-3311C322-BD0B-4379-AFF6-6D3AAD7EDE6FQ35687079-AE4E525C-274B-4D20-A6FC-9D71CDD635A8Q36215126-71BE67B6-C924-4E9E-BAAF-51BF8D9951E2Q37718978-F757AF8E-3C54-4A94-80EC-004CB4755B88Q38185119-C1E03188-9445-4939-ABF8-0A9EF6B1388BQ38195597-4CDB7424-BF2C-4266-BFD1-8EE903414FDBQ38510148-C8FBD968-141F-4DAB-86FD-9E2F14039A14Q38656496-A84B4349-8D61-4128-8AA9-CC27551D9A01Q40312408-052A0AB5-C43B-4D39-A863-A08A39BF0D21Q52723419-9D2A28BC-C6B5-4D8E-B2DB-B133B697922C
P2860
The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The design and proof of concep ...... ion against influenza A virus.
@ast
The design and proof of concep ...... ion against influenza A virus.
@en
type
label
The design and proof of concep ...... ion against influenza A virus.
@ast
The design and proof of concep ...... ion against influenza A virus.
@en
prefLabel
The design and proof of concep ...... ion against influenza A virus.
@ast
The design and proof of concep ...... ion against influenza A virus.
@en
P2093
P2860
P356
P1476
The design and proof of concep ...... ion against influenza A virus.
@en
P2093
Amabel C L Tan
Georgia Deliyannis
Lorena E Brown
Mandvi Bharadwaj
Weiguang Zeng
P2860
P2888
P304
P356
10.1038/ICB.2012.54
P577
2012-11-13T00:00:00Z
P6179
1004237348